Atyr_Logo.png
aTyr Pharma Announces Third Quarter 2023 Results and Provides Corporate Update
09 nov. 2023 16h00 HE | aTyr Pharma, Inc.
Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis expected to complete enrollment early in the second quarter of 2024. Phase 2 EFZO-CONNECT™ study of efzofitimod in SSc-ILD initiated...
cmi_logo.png
[Latest] Global Split Air Conditioning Systems Market Size/Share Worth USD 37.9 Billion by 2032 at a 5.7% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)
09 nov. 2023 15h30 HE | Custom Market Insights
Austin, TX, USA, Nov. 10, 2023 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Split Air Conditioning Systems Market Size, Trends and Insights By Application...
Life & Banc Split Corp.jpg
Life & Banc Split Corp. Completes Preferred Share Offering
31 oct. 2023 08h58 HE | Life & Banc Split Corp.
Not for distribution to U.S. newswire services or for dissemination in the United States. TORONTO, Oct. 31, 2023 (GLOBE NEWSWIRE) -- (TSX: LBS, LBS.PR.A) Life & Banc Split Banc Corp. (the...
Life & Banc Split Corp.jpg
Life & Banc Split Corp. Announces Successful Preferred Share Offering
18 oct. 2023 16h56 HE | Life & Banc Split Corp.
Not for distribution to U.S. newswire services or for dissemination in the United States. TORONTO, Oct. 18, 2023 (GLOBE NEWSWIRE) -- (TSX: LBS, LBS.PR.A) Life & Banc Split Banc Corp. (the...
Atyr_Logo.png
aTyr Pharma Presents Efzofitimod Data Demonstrating Statistically Significant Improvements in Time to Relapse, FVC and Patient Reported Outcomes
11 sept. 2023 08h00 HE | aTyr Pharma, Inc.
Post-hoc analysis from Phase 1b/2a study in pulmonary sarcoidosis presented at the European Respiratory Society (ERS) International Congress 2023. 7.7% of patients in the 3.0 and 5.0 mg/kg...
Life & Banc Split Corp.jpg
Life & Banc Split Corp. Announces Preferred Share Distribution Rate
28 août 2023 17h06 HE | Life & Banc Split Corp.
TORONTO, Aug. 28, 2023 (GLOBE NEWSWIRE) -- (TSX: LBS, LBS.PR.A) Life & Banc Split Corp. (the “Fund”) announces that the preferred share (the “Preferred Shares”) distribution rate for the new...
Klang-Lgog-ryb-rgb50.png
“The Life Cycle” Podcast from Klang Games Clarifies the Most Important Questions About the Future of Mankind
06 avr. 2023 09h30 HE | Klang Games
BERLIN, April 06, 2023 (GLOBE NEWSWIRE) -- Klang Games, the makers behind the sandbox simulation MMO game SEED, are not only concerned with the future of mankind and the colonization of exoplanets...
Life & Banc Split Corp.jpg
Life & Banc Split Corp. Announces Extension of Term
04 avr. 2023 16h36 HE | Life & Banc Split Corp.
TORONTO, April 04, 2023 (GLOBE NEWSWIRE) -- (TSX: LBS, LBS.PR.A) Life & Banc Split Corp. (the “Company”) is pleased to announce that the board of directors has approved an extension of the...
Atyr_Logo.png
aTyr Pharma and Foundation for Sarcoidosis Research Announce Town Hall Virtual Meeting on Sarcoidosis and Transitioning from Steroids to New and Investigational Therapies
20 mars 2023 08h00 HE | aTyr Pharma, Inc.
SAN DIEGO, March 20, 2023 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a clinical stage biotherapeutics company engaged in the discovery and development of first-in-class medicines from its...
Atyr_Logo.png
aTyr Pharma Announces Fourth Quarter and Full Year 2022 Results and Provides Corporate Update
09 mars 2023 16h00 HE | aTyr Pharma, Inc.
 Phase 3 EFZO-FIT™ study of efzofitimod in patients with pulmonary sarcoidosis enrolling in the U.S., Europe and Japan. Phase 2 proof-of-concept study of efzofitimod in patients with SSc-ILD expected...